Preclinical antiviral efficacy of BJT-778 reported at EASL
June 5, 2024
Concurrent infection with hepatitis B virus (HBV) and hepatitis delta virus (HDV) may lead to cirrhosis, fulminant hepatitis or hepatocellular carcinoma faster than infection with HBV alone.